1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66ADADF0B84784049652580300020C966
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-biopharma-digital-marketing-improve-roi-field-force-support-mobile-engagement?opendocument
18
19opendocument
203.80.4.76
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Digital Marketing

Optimizing Biopharma Digital Marketing: Insights to Improve Digital ROI, Field Force Support & Mobile Engagement

ID: 5429


Features:

7 Info Graphics

17 Data Graphics

280+ Metrics

1 Narratives


Pages/Slides: 31


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Optimizing Biopharma Digital Marketing: Insights to Improve Digital ROI, Field Force Support & Mobile Engagement”

STUDY OVERVIEW

Elite healthcare organizations are investing more than ever in digital marketing to learn about their customers, build better relationships, leverage effective online media, and - of course - grow revenue. However, with greater investment, digital marketers also face the onus of delivering maximum results with available resources.

Best Practices, LLC undertook benchmarking research to provide critical insights into how savvy biopharma digital marketers are using new tools and tactics to reduce cost, raise sales force effectiveness, and highlight critical trends in mobile customer engagement. This study will serve as a benchmark to drive digital marketing performance excellence in the healthcare industry.


KEY TOPICS

  • Reducing Digital Cost
  • Improving Sales Force Effectiveness
  • Use of Mobile Apps & Their Role in Decision Making
  • Use of Mobile Apps in Digital Health & Digital Medicine

KEY METRICS
  • Percentage of Total Digital Marketing Budget Allocated to Key Activities
  • Use of Various Digital Tools and Tactics to Reduce Overall Costs
  • Successful Approaches to Enhance Sales Force Effectiveness
  • State of Play for Healthcare Mobile Applications
  • High-ROI Mobile Engagement Programs
  • Effective Mobile Apps and Tools to Educate Customers, Inform Treatment Decisions & Enhance Decision Making
  • Effective Mobile Apps to Support Digital Health & Digital Medicine

SAMPLE KEY FINDINGS
  • Biopharma mobile footprint now includes regularly updated physician and patient applications: Close to two-thirds of benchmark DM teams have produced physician-oriented mobile applications, with 59% having also created patient-oriented apps and 23% creating apps for other customers (e.g., payers, KOLs). Mobile apps for core customer groups, sustained by regular updates to ensure relevance, have achieved solid uptake, with a high percentage of leading apps having succeeded in garnering more than 1,000 downloads. Digital health apps that may require FDA approval have been launched by 15% of companies; electronic health record-related apps are more rare (4%).


METHODOLOGY

Best Practices, LLC engaged 31 digital, multichannel marketing and other commercial leaders from 24 leading bio-pharmaceutical companies through a benchmarking survey instrument. Nearly 70% of participants serve at the level of director or above.


Industries Profiled:
Biopharmaceutical; Pharmaceutical; Medical Device; Manufacturing; Biotech; Consumer Products; Diagnostic; Health Care; Chemical; Consulting; Media


Companies Profiled:
Alkermes; Astellas; Baxter International; Bayer; CSL Behring; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline ; Insyght; Integra LifeSciences; Medi-Media; Merck; Mylan; Nektar Therapeutics; Novartis; Pfizer; Precision For Value; Prometheus Therapeutics & Diagnostics; Roche; Shionogi Inc.; Sunovion; Takeda Pharmaceuticals; Teva

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.